T2* in Transfusion Dependant Anemia, MI, LVF, Normal Patients
The purpose of this study is to provide accurate prognostic data linking cardiac complications to myocardial T2* values (A measure of iron levels in the heart using MRI)in patients predisposed to heart iron overload.
|Study Design:||Observational Model: Defined Population
Time Perspective: Longitudinal
|Official Title:||Incidence of Cardiac Complications in Patients With Cardiac Siderosis During 1 Year Follow−up and the Normal T2* Ranges in LVF, MI and Normal Population.|
|Study Start Date:||January 2007|
|Study Completion Date:||August 2007|
Key Definitions Myocardial siderosis - Iron deposition that occurs in the heart, usually in relation to recurrent blood transfusions and red cell breakdown.
Thalassaemia - A hereditary form of anaemia leading to recurrent blood transfusions and iron overload.
Cardiomyopathy - Disease of the heart leading to heart failure. In the case of cardiac siderosis it is entirely reversible.
Chelation - Drug used to remove iron from the heart T2* CMR - Cardiac Magnetic Resonance Imaging. A specialised scan that uses a large magnet to image the heart. As iron has magnetic properties we can use this scan to determine the amount of iron within the heart. T2* is a value that relates to the level of iron loading in the heart. A T2* of less than 10 relates to severe heart iron loading, a T2* of 10-20 relates to mild/moderate heart iron loading and a T2* of greater than 20 relates to no significant iron loading in the heart.
Heart failure - Disease in which the myocardium (heart muscle) weakens and can not pump blood efficiently. Fluid accumulates in the lungs, hands, ankles, or other parts of the body. The mortality from heart failure is very high.
Heterozygotes - An individual with one normal and one abnormal thalassaemia gene. They are carriers of the thalassaemia gene with milder clinical manifestations.
Homozygotes - An individual who has inherited both abnormal thalassaemia genes producing a more severe form of the disease.
Question Response Although a rare disease in the UK, thalassaemia is the commonest genetic disorder worldwide, with approximately 94 million heterozygotes for beta thalassaemia and 60,000 homozygotes born each year.
In the United Kingdom, despite relatively easy access to healthcare, approximately 50% of patients with thalassaemia major die before reaching the age of thirty five. Of those deaths, over 60% are a result of heart failure. The cardiomyopathy is reversible if chelation is commenced early but diagnosis is often delayed due to the late onset of symptoms and measurable LV dysfunction.
This study will provide strong evidence that a myocardial T2* <10ms represents a high risk of developing cardiac complications. Derived risk ratios will provide sound guidance as to when life saving chelation is required.
A database will be produced containing clinical data and T2* values on 665 thalassaemia patients from 1998-2006.
A diagnosis of heart failure will be made if the patient has had an ejection fraction of less than 55% (measured by CMR or echocardiography) and symptoms as per NHYA classification within 1 year of their CMR scan.
A diagnosis of arrhythmia was made if the patient had documented ECG evidence within 1 year of their CMR scan.
This information will be gathered retrospectively by access to outpatient clinic letters, hospital notes, CMR/ echo reports and clinical details recorded in a proforma at the time of the CMR scan. Some of the clinical data would be obtained from other hospitals.
Patient scans will only be used if between the dates of 1999-2005. As all other data is in respect to the year immediately post scan then no further data will be required on any patient post 2006.
Logistic regression will be used to determine whether T2* is predictive of cardiac complications in the 12 months after a patient's CMR scan. Since some patients will have more than 1 scan, a mixed model logistic regression will be used to take account of any within-patient correlation that may occur.
The data will be analysed by Dr Michael Roughton (Medical Statistician, Royal Brompton Hospital)
The results will be disseminated through peer review journals
Please refer to this study by its ClinicalTrials.gov identifier: NCT00520559
|Principal Investigator:||Dudley Pennell, MA, MD||Imperial College London|